Sugi Predict

Sugi Predict / Compounds / SCHEMBL587359

SCHEMBL587359

SCHEMBL587359

Clc1cc2cc[nH]c2cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 4/20 0.50
▸ NR4A2 P43354 2/20 0.50
▸ F7 P08709 1/20 0.50
▸ LTA4H P09960 1/20 0.50
▸ F3 P13726 1/20 0.50
▸ MAOB P27338 4/20 0.46
▸ CSNK2A1 P68400 1/20 0.46
▸ CMA1 P23946 1/20 0.45
▸ DYRK3 O43781 1/20 0.43
▸ CCNT1 O60563 1/20 0.43
▸ CCNA2 P20248 1/20 0.43
▸ CDK2 P24941 1/20 0.43
▸ CDK9 P50750 1/20 0.43
▸ CDK5 Q00535 1/20 0.43
▸ DYRK1A Q13627 1/20 0.43
▸ CDK5R1 Q15078 1/20 0.43
▸ DYRK2 Q92630 1/20 0.43
▸ DYRK1B Q9Y463 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1233148 0.83 AHR (0.50) AHRNR4A2F7LTA4HF3
SCHEMBL29433499 0.83 AHR (0.50) AHRNR4A2F7LTA4HF3
Ethoxycarbonyl Group SCHEMBL28038687 0.81 MAOB (0.38) AHRNR4A2F7LTA4HF3
SCHEMBL30768364 0.80 GABRP (0.36) AHRNR4A2F7LTA4HF3
SCHEMBL30354467 0.75 USP2 (0.50) AHRNR4A2F7LTA4HF3
SCHEMBL29975686 0.75 AHR (0.50) AHRNR4A2F7LTA4HF3
SCHEMBL8664673 0.75 PDPK1 (0.47) AHRNR4A2F7LTA4HF3
SCHEMBL30758727 0.75 CYP2A6 (0.47) AHRNR4A2F7LTA4HF3
SCHEMBL21090062 0.75 HDAC6 (0.43) AHRNR4A2F7LTA4HF3
SCHEMBL8296659 0.75 CYP2A6 (0.47) AHRNR4A2F7LTA4HF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070902-A1 SULFONYL DERIVATIVES AS CCR6 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2026-03-12 — — US disclosed
US-12570648-B2 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer LES LABORATOIRES SERVIER (FR) 2026-03-10 — — US disclosed
EP-4630402-A1 SULFONYL DERIVATIVES AS CCR6 INHIBITORS F. Hoffmann-La Roche AG (CH) 2025-10-15 — — EP disclosed
US-20250236621-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2025-07-24 — — US disclosed
WO-2025085852-A1 COMPOUNDS, COMPOSITIONS, AND METHODS NICO THERAPEUTICS, INC. (US) 2025-04-24 — — WO disclosed
CN-119562953-A Compound with kinase inhibition function and preparation and application thereof 上海轶诺药业有限公司 2025-03-04 — — CN disclosed
US-12240846-B2 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases ENLIVEN INC. (US) 2025-03-04 — — US disclosed
US-12208088-B2 Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof GENENTECH, INC. (US) 2025-01-28 — — US disclosed
CN-119019388-A 5-And 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase 英莱汶公司 2024-11-26 — — CN disclosed
WO-2024217523-A1 SELECTIVE TKY2 INHIBITORS AND USES THEREOF MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) 2024-10-24 — — WO disclosed
WO-2010117935-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT SCHERING CORPORATION (US) 2010-10-14 — — WO disclosed
WO-2010117935-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT SCHERING CORPORATION (US) 2010-10-14 — — WO disclosed
WO-2010042337-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY MERCK SHARP & DOHME CORP. (US) 2010-04-15 — — WO disclosed
CN-1025998-C 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines PFIZER (US) 1994-09-28 — — CN disclosed
EP-0379314-B1 3-(1,2,5,6-Tetrahydropyridyl)-pyrrolopyridines PFIZER (US) 1994-03-23 — — EP disclosed
US-5169947-A 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines PFIZER INC. (US) 1992-12-08 — — US disclosed
US-5051412-A Pharmaceutically active 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines PFIZER INC. (US) 1991-09-24 — — US disclosed
CN-1044465-A 3-(1,2,5, the 6-tetrahydro pyridyl)-pyrrolopyridine PFIZER (US) 1990-08-08 — — CN disclosed
WO-1990007926-A1 3-(1,2,5,6-TETRAHYDROPYRIDYL)-PYRROLOPYRIDINES PFIZER INC. (US) 1990-07-26 — — WO disclosed
EP-0379314-A1 3-(1,2,5,6-Tetrahydropyridyl)-pyrrolopyridines PFIZER INC. (US) 1990-07-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12208088-B2 Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof HIPK1, NEK1, HIPK2 AHR 2749/4885NR4A2 1189/4885F7 3502/4885
US-20250236621-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR AHR 1661/4885NR4A2 2366/4885F7 4522/4885
US-20260070902-A1 SULFONYL DERIVATIVES AS CCR6 INHIBITORS CCR6, CCR1, CCR4 AHR 271/4885NR4A2 423/4885F7 2081/4885
US-12570648-B2 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer BCOR, BCL2A1, BAK1 AHR 944/4885NR4A2 204/4885F7 3992/4885
US-12240846-B2 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases ABL1, ABL2, BCR AHR 1661/4885NR4A2 2366/4885F7 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.